Immunize with IPV
About the vaccine
Inactivated Poliovirus Vaccine (IPV) is key to the polio endgame. To safeguard against the withdrawal of the type 2 serotype, in November 2012 the SAGE recommended that at least one dose of IPV be introduced into all routine immunization programmes prior to the switch from tOPV to bOPV.
This IPV dose is expected to:
•prevent paralytic polio in individuals exposed to a cVDPV type 2 or WPV2;
•improve the immunological response to mOPV type 2 if required to be given in response to a WPV2 or cVDPV2 outbreak after tOPV cessation;
•reduce transmission of cVDPV type 2 or WPV2 should either be introduced after tOPV cessation;
•boost immunity to WPV1 and WPV3 in vaccine recipients, which may further accelerate WPV eradication.
IPV provides serum immunity to all three types of poliovirus, resulting in protection against paralytic poliomyelitis. As an injectable vaccine, it can be administered alone or in combination with other vaccines.